share_log

Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

Humanigen's Ifabotuzumab Shows Encouraging Action In Early-Stage Brain Cancer Study

Humanigen公司的Ifaotuzumab在早期腦癌研究中顯示出令人鼓舞的作用
Benzinga Real-time News ·  2021/04/09 20:28
  • Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and lethal primary brain cancer.
  • The results will be presented as a poster at the AACR Annual Meeting 2021.
  • In the study, ifabotuzumab demonstrated highly sensitive, specific, and reproducible targeting of the tumor and tumor microenvironment in all patients.
  • No dose-limiting toxicities were observed, and all adverse events were readily manageable.
  • The Phase 1 study was designed to determine the safety and recommended Phase 2 dose of ifabotuzumab.
  • Ifabotuzumab is a non-fucosylated IgG1κ antibody targeting the EphA3 receptor. EphA3 is a tumor-restricted antigen expressed in the tumor vasculature and tumor stroma of various solid tumors.
  • Additional studies are planned to evaluate ifabotuzumab as an antibody-drug conjugate in solid tumor patients.
  • Price Action: HGEN shares are trading 2.8% higher at $17.4 in the premarket session on the last check Friday.
  • Humanigen Inc.納斯達克市場代碼：HGEN)宣佈了評估其第二種Humaneered抗體ifobtuzumab的第一階段試驗結果，該抗體用於治療多形性膠質母細胞瘤(GBM)患者，GBM是最常見和最致命的原發性腦癌。
  • 結果將以海報的形式在AACR 2021年年會上公佈。
  • 在這項研究中，ifobtuzumab對所有患者的腫瘤和腫瘤微環境顯示出高度敏感、特異和可重複性的靶向。
  • 沒有觀察到劑量限制毒性，所有不良事件都很容易控制。
  • 第一階段研究的目的是確定ifobtuzumab的安全性和推薦的第二階段劑量。
  • Ifaotuzumab是一種針對EphA3受體的非巖藻糖基化IgG1型κ抗體。EphA3是一種腫瘤限制性抗原，表達於多種實體瘤的腫瘤血管和腫瘤間質中。
  • 計劃進行更多的研究來評估ifobtuzumab作為實體腫瘤患者的抗體-藥物結合物。
  • 價格行動：在週五的最後一次檢查中，HGEN股價在盤前交易時段上漲2.8%，至17.4美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論